ERBB2 and breast carcinoma: Most prominent ADCs include brentuximab vedotin, effective for Hodgkin's lymphoma and systemic anaplastic large cell lymphoma [53], and ado-trastuzumab emtansine, approved by the FDA for HER2-positive breast cancer [55].